Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juil. 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock...
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
14 juin 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
09 juin 2021 16h15 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 juin 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock...
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
02 juin 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
13 mai 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an...
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
12 mai 2021 16h01 HE
|
Flexion Therapeutics, Inc.
Flexion reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $24.6 millionDavid Arkowitz, CFO, stepping down effective May 31,2021, and will be succeeded by...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock...
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
05 mai 2021 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S....
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
28 avr. 2021 07h30 HE
|
Flexion Therapeutics, Inc.
Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-toleratedTwo of five patients...